Hege Fredriksen Berg

Stipendiat

Vitenskapelig artikkel

Vis forfatter(e) (2021). Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. Communications Medicine. 1-14.
Vis forfatter(e) (2021). Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer. Journal of Translational Medicine. 1-13.
Vis forfatter(e) (2021). A radiogenomics application for prognostic profiling of endometrial cancer. Communications Biology. 12 sider.

Vis forfatter(e) (2020). Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers. 1-18.
Vis forfatter(e) (2020). Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. Gynecologic Oncology. 1-9.
Vis forfatter(e) (2020). High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology. 260-267.
Vis forfatter(e) (2020). Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer. 1014-1022.

Vis forfatter(e) (2019). Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. PLOS ONE. 1-13.

Vis forfatter(e) (2018). Blood steroids are associated with prognosis and fat distribution in endometrial cancer. Gynecologic Oncology. 46-52.

Vis forfatter(e) (2017). HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
Vis forfatter(e) (2017). Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. Gynecologic Oncology. 197-203.